Drug intelligence / Profile preview

tigatuzumab + gemcitabine

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Combination therapy of **tigatuzumab** (formerly known as CS-1008), a humanized monoclonal antibody targeting death receptor 5 (DR5), and **gemcitabine**, a nucleoside analog chemotherapeutic agent. Tigatuzumab induces apoptosis in tumor cells by binding DR5 and activating the caspase cascade, while gemcitabine inhibits DNA synthesis. This combination was investigated for the treatment of chemotherapy-naive patients with unresectable or metastatic pancreatic cancer, showing clinical activity and tolerability in phase 2 studies[2][4].

Other names: CS-1008 + gemcitabinetigatuzumab + gemcitabine

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on tigatuzumab + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tigatuzumab + gemcitabine.

Explore the full profile